The SLC29A2 antibody is a research tool targeting the solute carrier family 29 member 2 (SLC29A2), a protein encoded by the SLC29A2 gene in humans. Also known as equilibrative nucleoside transporter 2 (ENT2), SLC29A2 facilitates bidirectional transport of nucleosides and nucleobases across cell membranes, playing a critical role in cellular nucleoside homeostasis, drug uptake (e.g., anticancer and antiviral agents), and purinergic signaling. This transporter is widely expressed in tissues such as the liver, kidney, placenta, and brain.
SLC29A2 antibodies are commonly used to study the protein's expression, localization, and function in physiological and pathological contexts. Polyclonal or monoclonal antibodies are designed to recognize specific epitopes of SLC29A2. enabling applications like Western blotting, immunohistochemistry, immunofluorescence, and flow cytometry. Researchers utilize these antibodies to investigate SLC29A2's involvement in diseases, including cancer (e.g., chemoresistance mechanisms), metabolic disorders, and neurological conditions linked to altered nucleoside transport.
Validation of antibody specificity is critical, often confirmed via knockout cell lines or siRNA-mediated gene silencing. Commercial SLC29A2 antibodies are typically accompanied by datasheets detailing immunogen sequences, host species, and recommended experimental conditions. As dysregulation of SLC29A2 impacts drug efficacy and cellular metabolism, its study remains relevant for therapeutic development and understanding disease mechanisms.